Sorrento Announces Presentation of Data from Clinical Study of Resiniferatoxin for Intractable Cancer Pain at ASRA Meeting - San Francisco Business Times | Lung Cancer Dispatch | Scoop.it

"Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that investigators from the National Institutes of Health (NIH) presented data highlighting results from the first two dosing cohorts of the Phase I/II trial of resiniferatoxin (RTX) for the treatment of intractable cancer pain. The data were presented at the 39th Annual Regional Anesthesia and Acute Pain Meeting, organized by the American Society of Regional Anesthesia and Pain Medicine (ASRA), in Chicago on April 3, 2014.


"Data from six patients with advanced cancer and severe refractory pain, who received either 13 or 26 mcg injection of RTX into the intrathecal space, showed a clinically meaningful improvement in quality of life following the single injection."